|
Indications and Dosage
Oral
Erythema nodosum leprosum (Type 2) Adult: 100-300 mg once daily at bedtime, reduced gradually by 50 mg every 2-4 wk once a satisfactory reponse is achieved. Not for monotherapy if moderate or severe neuritis present. Max: 400 mg/day. Patients < 50 kg: Initially, 100 mg daily. Oral Multiple myeloma Adult: Initial dose of 200 mg once daily, increased by 100 mg at wkly intervals according to patient tolerance. Max: 800 mg daily.
|
|
Administration
Should be taken on an empty stomach. Take at least 1 hr after a meal, w/ a full glass of water.
|
|
Contraindications
Pregnancy and lactation.
|
|
Special Precautions
All females of childbearing potential must use 2 reliable forms of contraception simultaneously 4 wk before starting therapy, during and 4 wk after therapy is discontinued. Therapy to be stopped immediately if pregnancy occurs. Male: Use of barrier methods of contraception if partner is of child-bearing potential. Do not donate blood or sperm during therapy. Patient should not drive or operate machinery. Discontinue therapy if any skin rash develops. Do not resume therapy if the rash is exfoliative, purpuric, or bullous, or if Stevens-Johnson syndrome or toxic epidermal necrolysis suspected.
|
|
Adverse Reactions
Severe and irreversible peripheral neuropathy, constipation, dizziness, orthostatic hypotension, drowsiness, somnolence, bradycardia, increase of viral load in HIV-infected patients, hypersensitivity reaction.
Potentially Fatal: Stevens-Johnson syndrome, toxic epidermal necrolysis and blood dyscrasias. |
|
Drug Interactions
Thalidomide enhances sedative activity of barbiturates, alcohol, chlorpromazine and reserpine. Avoid use of other drugs that have the potential to cause peripheral neuropathy. Increased risk of thromboembolic events with darbepoetin-alfa and doxorubicin.
Potentially Fatal: Increased risk of bone marrow supression with peg interferon alfa. |
|
Action
Description: Thalidomide is a synthetic glutamic acid derivative immunomodulator with anti-inflammatory, antiangiogenetic, sedative and hypnotic activity.
Pharmacokinetics: Absorption: Slowly absorbed from GI tract. Peak plasma concentrations: 3 to 6 hr. Food may delay but does not significantly affect extent of absorption of thalidomide. Distribution: Crosses the placenta, distributed into the semen. Elimination half-life: 5-7 hr. Metabolism: Exact metabolic fate unknown, it appears to undergo non-enzymatic hydrolysis in plasma. |
|
MIMS Class
|
Manage Account
Change Password
Sign Out
